ADX-71441

ADX71441
Names
	IUPAC name N-[5-[4-[(4-chloro-3-fluorophenyl)methyl]-6-methoxy-3,5-dioxo-1,2,4-triazin-2-yl]-2-fluorophenyl]acetamide
Identifiers
CAS Number	1207440-88-7;
3D model (JSmol)	Interactive image;
PubChem CID	25106292;
	InChI Key: BQDMEJYNGXEHSW-UHFFFAOYSA-N; InChI=1S/C19H15ClF2N4O4/c1-10(27)23-16-8-12(4-6-14(16)21)26-19(29)25(18(28)17(24-26)30-2)9-11-3-5-13(20)15(22)7-11/h3-8H,9H2,1-2H3,(H,23,27);
	SMILES CC(=O)NC1=C(C=CC(=C1)N2C(=O)N(C(=O)C(=N2)OC)CC3=CC(=C(C=C3)Cl)F)F;
Properties
Chemical formula	C19H15ClF2N4O4
Molar mass	436.80 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

ADX-71441 is a GABA_B receptor positive allosteric modulator currently being investigated as a potential treatment for anxiety, epilepsy, pain and other conditions.

Therapeutic potential

ADX-71441 has been shown to reduce alcohol consumption.^[1] This result was observed in both alcohol dependent and non-dependent animals.^[2]

There were also trials about nicotine addiction, which showed positive results: ADX-71441 was able to decrease some withdrawal symptoms of nicotine withdrawal.^[3]

This compound has also been shown to reduce anxiety in people with PTSD.^[4]

Experiments have shown that this compound was able to decrease hypersensitivity to pain in mice, Guinea pigs and rats.^[4]

ADX-71441 has been shown to have less tolerance and side effects than direct GABA_B agonists, such as baclofen.^[2]